PhaseBio Pharmaceuticals (NASDAQ:PHAS) Downgraded by Zacks Investment Research to Hold

0
58

PhaseBio Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  PhaseBio Pharmaceuticals Downgraded by Zacks Investment Research on 10/19/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of PhaseBio Pharmaceuticals traded no change $0.00 on Monday, reaching $3.85. 127335 shares of the stock traded hands, compared to its average volume of 400051. Shares of PhaseBio Pharmaceuticals were trading at $3.85 on Monday. The firm’s 50 day moving average is $3.25 and its 200 day moving average is $3.57.PhaseBio Pharmaceuticals has a 12 month low of $3.74 and a 12 month high of $5.83. While on yearly highs and lows, PhaseBio Pharmaceuticals’s today has traded high as $3.90 and has touched $3.74 on the downward trend. See More Analyst Rating at: RATING

PhaseBio Pharmaceuticals Earnings and What to expect: 

PhaseBio Pharmaceuticals last released its earnings results on August 12th, 2021. The reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.14. The business had revenue of $10.34 million for the quarter. PhaseBio Pharmaceuticals has generated ($3.39) earnings per share over the last year (($3.36) diluted earnings per share). Earnings for PhaseBio Pharmaceuticals are expected to grow in the coming year, from ($2.57) to ($2.19) per share. PhaseBio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for PhaseBio Pharmaceuticals are expected to grow in the coming year, from ($2.57) to ($2.19) per share. The P/E ratio of PhaseBio Pharmaceuticals is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of PhaseBio Pharmaceuticals is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Moving Average Technical Analysis

5 day Moving Average is $3.91 And 5 day price change is -$0.08 (-2.00%)  with average volume for 5 day average is 400,583. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $3.41 and 20 day price change is $0.89 (31.00%) and average 20 day moving volume is 359,636. 50 day moving average is $3.25  and 50 day price change is $0.39 ( 11.62%)  and with average volume for 50 days is : 344,330. 200 day moving average is $3.57  and 200 day price change is $0.04 (0.0115)  and with average volume for 200 days is : 450,267.

Other owners latest trading in PhaseBio Pharmaceuticals :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 10,254 which equates to market value of $38K and appx 0.00% owners of PhaseBio Pharmaceuticals
  • On 8/27/2021 shares held by Endurant Capital Management LP were 2,129,709 which equates to market value of $7.92M and appx 2.20% owners of PhaseBio Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 129,081 which equates to market value of $0.48M and appx 0.00% owners of PhaseBio Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 63.42% for PhaseBio Pharmaceuticals

See More Analyst Rating at: RATING